ID

38509

Description

A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection; ODM derived from: https://clinicaltrials.gov/show/NCT01402908

Link

https://clinicaltrials.gov/show/NCT01402908

Keywords

  1. 10/23/19 10/23/19 -
  2. 9/20/21 9/20/21 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

October 23, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Cancer NCT01402908

Eligibility Cancer NCT01402908

  1. StudyEvent: Eligibility
    1. Eligibility Cancer NCT01402908
Criteria
Description

Criteria

1. histologically-proven primary hepatocellular carcinoma with curative resection performed in the 4 - 6 weeks prior to randomization.
Description

Excision Curative Liver carcinoma

Data type

boolean

Alias
UMLS CUI [1,1]
C0728940
UMLS CUI [1,2]
C1276305
UMLS CUI [1,3]
C2239176
2. age ≥ 18 years.
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
3. written, signed and dated informed consent to participate in study
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
4. ecog performance status 0 to 1
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
5. child pugh score ≤ 8
Description

Child-Pugh Classification

Data type

boolean

Alias
UMLS CUI [1]
C2347612
6. platelet count ≥ 80 x 109 cells/liter
Description

Platelet Count measurement

Data type

boolean

Alias
UMLS CUI [1]
C0032181
7. pt-inr ≤ 1.3
Description

Prothrombin time international normalized ratio (PT-INR)

Data type

boolean

Alias
UMLS CUI [1]
C1821762
8. aptt ≤ upper limit of normal
Description

Activated Partial Thromboplastin Time measurement

Data type

boolean

Alias
UMLS CUI [1]
C0030605
key exclusion criteria:
Description

Exclusion Criteria Main

Data type

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1542147
1. pathological confirmation of single tumor < 2 cm in diameter which obtained from the most recent hepatectomy.
Description

Single tumor Diameter | Hepatectomy

Data type

boolean

Alias
UMLS CUI [1,1]
C1298180
UMLS CUI [1,2]
C1301886
UMLS CUI [2]
C0019144
2. history of immune-mediated thrombocytopenia other platelet abnormalities or other hereditary or acquired coagulopathies, or laboratory evidence of anti-heparin antibodies, or any previous history of having tested positive for anti-heparin antibodies.
Description

Immune-mediated thrombocytopenia | Abnormal platelets | Hereditary coagulopathy | Blood Coagulation Disorder Acquired | Heparin antibody | Heparin antibody Test Positive

Data type

boolean

Alias
UMLS CUI [1]
C0272286
UMLS CUI [2]
C0151854
UMLS CUI [3]
C0679428
UMLS CUI [4,1]
C0005779
UMLS CUI [4,2]
C0439661
UMLS CUI [5]
C0369324
UMLS CUI [6,1]
C0369324
UMLS CUI [6,2]
C0039593
UMLS CUI [6,3]
C1514241
3. any evidence of tumor metastasis or co-existing malignant disease
Description

Neoplasm Metastasis | Cancer Other

Data type

boolean

Alias
UMLS CUI [1]
C0027627
UMLS CUI [2]
C1707251
4. any prior recurrence of hcc or any liver resection prior to the most recent procedure
Description

Recurrent Hepatocellular Carcinoma | Hepatectomy

Data type

boolean

Alias
UMLS CUI [1]
C0861876
UMLS CUI [2]
C0019144
5. clinically significant non-malignant disease including, but not limited to, surgery within 6 weeks of randomization (apart from liver resection and re-operation for complications of liver resection), active clinically significant infection within 6 weeks prior to randomization, myocardial infarction within 6 months prior to randomization, cerebrovascular event within 12 months prior to randomization or clinically-significant gastrointestinal bleeding within 12 months prior to randomization. subjects who have experienced post-operative complications of liver resection may be enrolled providing that such complications are fully resolved at the time of screening.
Description

Disease Except Malignant disease | Operative Surgical Procedure | Exception Hepatectomy | Exception Repeat Surgery Complications Hepatectomy | Communicable Disease | Myocardial Infarction | Cerebrovascular accident | Gastrointestinal Hemorrhage | Postoperative Complications Hepatectomy | Postoperative Complications resolved

Data type

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0332300
UMLS CUI [1,3]
C0442867
UMLS CUI [2]
C0543467
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0019144
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0035110
UMLS CUI [4,3]
C0009566
UMLS CUI [4,4]
C0019144
UMLS CUI [5]
C0009450
UMLS CUI [6]
C0027051
UMLS CUI [7]
C0038454
UMLS CUI [8]
C0017181
UMLS CUI [9,1]
C0032787
UMLS CUI [9,2]
C0019144
UMLS CUI [10,1]
C0032787
UMLS CUI [10,2]
C1514893
6. subjects with uncontrolled infection or serious infection within the past 4 weeks.
Description

Communicable Disease Uncontrolled | Communicable Disease Serious

Data type

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0205318
UMLS CUI [2,1]
C0009450
UMLS CUI [2,2]
C0205404
7. history of prior hcc therapy including chemotherapy, radiotherapy, molecular targeting agents, vaccines, transarterial embolization (tae), transarterial chemoembolization (tace), liver transplantation or surgical resection prior to the most recent hepatectomy, at any time prior to randomization. this includes pre-, peri- and post-operative treatments. pre-operative portal vein embolization is permitted. subjects should not be enrolled if, at the time of randomization, it is planned that they will subsequently undergo liver transplantation regardless of tumor recurrence.
Description

Prior Therapy Liver carcinoma | Chemotherapy | Therapeutic radiology procedure | Molecular Targeted Therapy | Vaccines | Transarterial embolization | Transarterial Chemoembolization | Transplantation of liver | Excision prior to Hepatectomy | Neoadjuvant Therapy | Perioperative Care | Postoperative Care | Embolization of portal vein Preoperative allowed | Transplantation of liver Planned

Data type

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C2239176
UMLS CUI [2]
C0392920
UMLS CUI [3]
C1522449
UMLS CUI [4]
C2699893
UMLS CUI [5]
C0042210
UMLS CUI [6]
C3163695
UMLS CUI [7]
C3539919
UMLS CUI [8]
C0023911
UMLS CUI [9,1]
C0728940
UMLS CUI [9,2]
C0332152
UMLS CUI [9,3]
C0019144
UMLS CUI [10]
C0600558
UMLS CUI [11]
C0150706
UMLS CUI [12]
C0032786
UMLS CUI [13,1]
C0578122
UMLS CUI [13,2]
C0445204
UMLS CUI [13,3]
C0683607
UMLS CUI [14,1]
C0023911
UMLS CUI [14,2]
C1301732
8. concomitant use of aspirin (> 150 mg/day), vitamin k antagonists (other than low-dose prophylactic use), heparin within two weeks prior to randomization, or other anti-platelet drugs (e.g. abciximab, clopidogrel, dipyridamole, ticlopidine and tirofiban). low dose aspirin (≤ 150 mg/day) and low-dose prophylactic vitamin k antagonists (e.g. warfarin ≤ 1 mg/day) are permitted as concomitant medications.
Description

Aspirin U/day | Vitamin K antagonists | Exception Prophylactic treatment Low dose | heparin | Antiplatelet Agents | abciximab | clopidogrel | Dipyridamole | Ticlopidine | tirofiban

Data type

boolean

Alias
UMLS CUI [1,1]
C0004057
UMLS CUI [1,2]
C0456683
UMLS CUI [2]
C3653316
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0199176
UMLS CUI [3,3]
C0445550
UMLS CUI [4]
C0019134
UMLS CUI [5]
C0085826
UMLS CUI [6]
C0288672
UMLS CUI [7]
C0070166
UMLS CUI [8]
C0012582
UMLS CUI [9]
C0040207
UMLS CUI [10]
C0247025
9. history of allergic, anaphylactic or other significant adverse reaction to radiographic contrast media (iodinated or non-iodinated), which cannot be managed by pre-treatment with agents such as steroids or anti-histamines, and which, in the opinion of the investigator, renders the subject unsuitable for routine ct scanning. subjects who are contra-indicated for ct scanning for other reasons (e.g. ferromagnetic implants, profound claustrophobia), should not be enrolled.
Description

Allergy to X-ray contrast media | Allergic reaction to iodinated contrast material | Allergic Reaction Non-iodinated X-ray contrast media | Anaphylaxis reaction to contrast material | Pretreatment Steroids Unsuccessful | Pretreatment Histamine Antagonists Unsuccessful | Study Subject Inappropriate CT scanning | Medical contraindication CT scanning | Magnetic metal Implants | Claustrophobia Profound

Data type

boolean

Alias
UMLS CUI [1]
C0570563
UMLS CUI [2]
C2215738
UMLS CUI [3,1]
C1527304
UMLS CUI [3,2]
C0361987
UMLS CUI [4]
C2215729
UMLS CUI [5,1]
C3539076
UMLS CUI [5,2]
C0038317
UMLS CUI [5,3]
C1272705
UMLS CUI [6,1]
C3539076
UMLS CUI [6,2]
C0019590
UMLS CUI [6,3]
C1272705
UMLS CUI [7,1]
C0681850
UMLS CUI [7,2]
C1548788
UMLS CUI [7,3]
C0040405
UMLS CUI [8,1]
C1301624
UMLS CUI [8,2]
C0040405
UMLS CUI [9,1]
C0439876
UMLS CUI [9,2]
C0021102
UMLS CUI [10,1]
C0008909
UMLS CUI [10,2]
C0439808
10. subjects with history of inflammatory bowel disease, any other abnormal bleeding tendency, or subjects at risk of bleeding due to open wounds or planned surgery.
Description

Inflammatory Bowel Disease | Bleeding tendency Abnormal | Bleeding risk Due to Open wound | Bleeding risk Due to Surgery Planned

Data type

boolean

Alias
UMLS CUI [1]
C0021390
UMLS CUI [2,1]
C1458140
UMLS CUI [2,2]
C0205161
UMLS CUI [3,1]
C3251812
UMLS CUI [3,2]
C0678226
UMLS CUI [3,3]
C0332798
UMLS CUI [4,1]
C3251812
UMLS CUI [4,2]
C0678226
UMLS CUI [4,3]
C0543467
UMLS CUI [4,4]
C1301732
11. women who are pregnant or breast-feeding or women of child-bearing potential who are unable or unwilling to practice a highly effective means of contraception.
Description

Pregnancy | Breast Feeding | Childbearing Potential Contraceptive methods Unable | Childbearing Potential Contraceptive methods Unwilling

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C3831118
UMLS CUI [3,2]
C0700589
UMLS CUI [3,3]
C1299582
UMLS CUI [4,1]
C3831118
UMLS CUI [4,2]
C0700589
UMLS CUI [4,3]
C0558080
12. active substance abuse, including alcohol, which, in the opinion of the investigator, risks impairing the ability of the subject to comply with the protocol.
Description

Substance Use Disorders Impairing Protocol Compliance

Data type

boolean

Alias
UMLS CUI [1,1]
C0038586
UMLS CUI [1,2]
C0221099
UMLS CUI [1,3]
C0525058
13. subjects who received other investigational or anti-neoplastic medication within the past 4 weeks.
Description

Investigational New Drugs | Antineoplastic Agents

Data type

boolean

Alias
UMLS CUI [1]
C0013230
UMLS CUI [2]
C0003392
14. current participation in any other clinical study or research project which involves administration of a pharmaceutical product or experimental treatment, or which involves protocol-specified laboratory tests, imaging studies or other investigations.
Description

Study Subject Participation Status | Investigational New Drugs | Therapy, Investigational | Laboratory Procedures | Imaging studies | Scientific investigation

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
UMLS CUI [3]
C0949266
UMLS CUI [4]
C0022885
UMLS CUI [5]
C1881134
UMLS CUI [6]
C0683933

Similar models

Eligibility Cancer NCT01402908

  1. StudyEvent: Eligibility
    1. Eligibility Cancer NCT01402908
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Excision Curative Liver carcinoma
Item
1. histologically-proven primary hepatocellular carcinoma with curative resection performed in the 4 - 6 weeks prior to randomization.
boolean
C0728940 (UMLS CUI [1,1])
C1276305 (UMLS CUI [1,2])
C2239176 (UMLS CUI [1,3])
Age
Item
2. age ≥ 18 years.
boolean
C0001779 (UMLS CUI [1])
Informed Consent
Item
3. written, signed and dated informed consent to participate in study
boolean
C0021430 (UMLS CUI [1])
ECOG performance status
Item
4. ecog performance status 0 to 1
boolean
C1520224 (UMLS CUI [1])
Child-Pugh Classification
Item
5. child pugh score ≤ 8
boolean
C2347612 (UMLS CUI [1])
Platelet Count measurement
Item
6. platelet count ≥ 80 x 109 cells/liter
boolean
C0032181 (UMLS CUI [1])
Prothrombin time international normalized ratio (PT-INR)
Item
7. pt-inr ≤ 1.3
boolean
C1821762 (UMLS CUI [1])
Activated Partial Thromboplastin Time measurement
Item
8. aptt ≤ upper limit of normal
boolean
C0030605 (UMLS CUI [1])
Exclusion Criteria Main
Item
key exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Single tumor Diameter | Hepatectomy
Item
1. pathological confirmation of single tumor < 2 cm in diameter which obtained from the most recent hepatectomy.
boolean
C1298180 (UMLS CUI [1,1])
C1301886 (UMLS CUI [1,2])
C0019144 (UMLS CUI [2])
Immune-mediated thrombocytopenia | Abnormal platelets | Hereditary coagulopathy | Blood Coagulation Disorder Acquired | Heparin antibody | Heparin antibody Test Positive
Item
2. history of immune-mediated thrombocytopenia other platelet abnormalities or other hereditary or acquired coagulopathies, or laboratory evidence of anti-heparin antibodies, or any previous history of having tested positive for anti-heparin antibodies.
boolean
C0272286 (UMLS CUI [1])
C0151854 (UMLS CUI [2])
C0679428 (UMLS CUI [3])
C0005779 (UMLS CUI [4,1])
C0439661 (UMLS CUI [4,2])
C0369324 (UMLS CUI [5])
C0369324 (UMLS CUI [6,1])
C0039593 (UMLS CUI [6,2])
C1514241 (UMLS CUI [6,3])
Neoplasm Metastasis | Cancer Other
Item
3. any evidence of tumor metastasis or co-existing malignant disease
boolean
C0027627 (UMLS CUI [1])
C1707251 (UMLS CUI [2])
Recurrent Hepatocellular Carcinoma | Hepatectomy
Item
4. any prior recurrence of hcc or any liver resection prior to the most recent procedure
boolean
C0861876 (UMLS CUI [1])
C0019144 (UMLS CUI [2])
Disease Except Malignant disease | Operative Surgical Procedure | Exception Hepatectomy | Exception Repeat Surgery Complications Hepatectomy | Communicable Disease | Myocardial Infarction | Cerebrovascular accident | Gastrointestinal Hemorrhage | Postoperative Complications Hepatectomy | Postoperative Complications resolved
Item
5. clinically significant non-malignant disease including, but not limited to, surgery within 6 weeks of randomization (apart from liver resection and re-operation for complications of liver resection), active clinically significant infection within 6 weeks prior to randomization, myocardial infarction within 6 months prior to randomization, cerebrovascular event within 12 months prior to randomization or clinically-significant gastrointestinal bleeding within 12 months prior to randomization. subjects who have experienced post-operative complications of liver resection may be enrolled providing that such complications are fully resolved at the time of screening.
boolean
C0012634 (UMLS CUI [1,1])
C0332300 (UMLS CUI [1,2])
C0442867 (UMLS CUI [1,3])
C0543467 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0019144 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0035110 (UMLS CUI [4,2])
C0009566 (UMLS CUI [4,3])
C0019144 (UMLS CUI [4,4])
C0009450 (UMLS CUI [5])
C0027051 (UMLS CUI [6])
C0038454 (UMLS CUI [7])
C0017181 (UMLS CUI [8])
C0032787 (UMLS CUI [9,1])
C0019144 (UMLS CUI [9,2])
C0032787 (UMLS CUI [10,1])
C1514893 (UMLS CUI [10,2])
Communicable Disease Uncontrolled | Communicable Disease Serious
Item
6. subjects with uncontrolled infection or serious infection within the past 4 weeks.
boolean
C0009450 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
Prior Therapy Liver carcinoma | Chemotherapy | Therapeutic radiology procedure | Molecular Targeted Therapy | Vaccines | Transarterial embolization | Transarterial Chemoembolization | Transplantation of liver | Excision prior to Hepatectomy | Neoadjuvant Therapy | Perioperative Care | Postoperative Care | Embolization of portal vein Preoperative allowed | Transplantation of liver Planned
Item
7. history of prior hcc therapy including chemotherapy, radiotherapy, molecular targeting agents, vaccines, transarterial embolization (tae), transarterial chemoembolization (tace), liver transplantation or surgical resection prior to the most recent hepatectomy, at any time prior to randomization. this includes pre-, peri- and post-operative treatments. pre-operative portal vein embolization is permitted. subjects should not be enrolled if, at the time of randomization, it is planned that they will subsequently undergo liver transplantation regardless of tumor recurrence.
boolean
C1514463 (UMLS CUI [1,1])
C2239176 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
C2699893 (UMLS CUI [4])
C0042210 (UMLS CUI [5])
C3163695 (UMLS CUI [6])
C3539919 (UMLS CUI [7])
C0023911 (UMLS CUI [8])
C0728940 (UMLS CUI [9,1])
C0332152 (UMLS CUI [9,2])
C0019144 (UMLS CUI [9,3])
C0600558 (UMLS CUI [10])
C0150706 (UMLS CUI [11])
C0032786 (UMLS CUI [12])
C0578122 (UMLS CUI [13,1])
C0445204 (UMLS CUI [13,2])
C0683607 (UMLS CUI [13,3])
C0023911 (UMLS CUI [14,1])
C1301732 (UMLS CUI [14,2])
Aspirin U/day | Vitamin K antagonists | Exception Prophylactic treatment Low dose | heparin | Antiplatelet Agents | abciximab | clopidogrel | Dipyridamole | Ticlopidine | tirofiban
Item
8. concomitant use of aspirin (> 150 mg/day), vitamin k antagonists (other than low-dose prophylactic use), heparin within two weeks prior to randomization, or other anti-platelet drugs (e.g. abciximab, clopidogrel, dipyridamole, ticlopidine and tirofiban). low dose aspirin (≤ 150 mg/day) and low-dose prophylactic vitamin k antagonists (e.g. warfarin ≤ 1 mg/day) are permitted as concomitant medications.
boolean
C0004057 (UMLS CUI [1,1])
C0456683 (UMLS CUI [1,2])
C3653316 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0199176 (UMLS CUI [3,2])
C0445550 (UMLS CUI [3,3])
C0019134 (UMLS CUI [4])
C0085826 (UMLS CUI [5])
C0288672 (UMLS CUI [6])
C0070166 (UMLS CUI [7])
C0012582 (UMLS CUI [8])
C0040207 (UMLS CUI [9])
C0247025 (UMLS CUI [10])
Allergy to X-ray contrast media | Allergic reaction to iodinated contrast material | Allergic Reaction Non-iodinated X-ray contrast media | Anaphylaxis reaction to contrast material | Pretreatment Steroids Unsuccessful | Pretreatment Histamine Antagonists Unsuccessful | Study Subject Inappropriate CT scanning | Medical contraindication CT scanning | Magnetic metal Implants | Claustrophobia Profound
Item
9. history of allergic, anaphylactic or other significant adverse reaction to radiographic contrast media (iodinated or non-iodinated), which cannot be managed by pre-treatment with agents such as steroids or anti-histamines, and which, in the opinion of the investigator, renders the subject unsuitable for routine ct scanning. subjects who are contra-indicated for ct scanning for other reasons (e.g. ferromagnetic implants, profound claustrophobia), should not be enrolled.
boolean
C0570563 (UMLS CUI [1])
C2215738 (UMLS CUI [2])
C1527304 (UMLS CUI [3,1])
C0361987 (UMLS CUI [3,2])
C2215729 (UMLS CUI [4])
C3539076 (UMLS CUI [5,1])
C0038317 (UMLS CUI [5,2])
C1272705 (UMLS CUI [5,3])
C3539076 (UMLS CUI [6,1])
C0019590 (UMLS CUI [6,2])
C1272705 (UMLS CUI [6,3])
C0681850 (UMLS CUI [7,1])
C1548788 (UMLS CUI [7,2])
C0040405 (UMLS CUI [7,3])
C1301624 (UMLS CUI [8,1])
C0040405 (UMLS CUI [8,2])
C0439876 (UMLS CUI [9,1])
C0021102 (UMLS CUI [9,2])
C0008909 (UMLS CUI [10,1])
C0439808 (UMLS CUI [10,2])
Inflammatory Bowel Disease | Bleeding tendency Abnormal | Bleeding risk Due to Open wound | Bleeding risk Due to Surgery Planned
Item
10. subjects with history of inflammatory bowel disease, any other abnormal bleeding tendency, or subjects at risk of bleeding due to open wounds or planned surgery.
boolean
C0021390 (UMLS CUI [1])
C1458140 (UMLS CUI [2,1])
C0205161 (UMLS CUI [2,2])
C3251812 (UMLS CUI [3,1])
C0678226 (UMLS CUI [3,2])
C0332798 (UMLS CUI [3,3])
C3251812 (UMLS CUI [4,1])
C0678226 (UMLS CUI [4,2])
C0543467 (UMLS CUI [4,3])
C1301732 (UMLS CUI [4,4])
Pregnancy | Breast Feeding | Childbearing Potential Contraceptive methods Unable | Childbearing Potential Contraceptive methods Unwilling
Item
11. women who are pregnant or breast-feeding or women of child-bearing potential who are unable or unwilling to practice a highly effective means of contraception.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C3831118 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
C1299582 (UMLS CUI [3,3])
C3831118 (UMLS CUI [4,1])
C0700589 (UMLS CUI [4,2])
C0558080 (UMLS CUI [4,3])
Substance Use Disorders Impairing Protocol Compliance
Item
12. active substance abuse, including alcohol, which, in the opinion of the investigator, risks impairing the ability of the subject to comply with the protocol.
boolean
C0038586 (UMLS CUI [1,1])
C0221099 (UMLS CUI [1,2])
C0525058 (UMLS CUI [1,3])
Investigational New Drugs | Antineoplastic Agents
Item
13. subjects who received other investigational or anti-neoplastic medication within the past 4 weeks.
boolean
C0013230 (UMLS CUI [1])
C0003392 (UMLS CUI [2])
Study Subject Participation Status | Investigational New Drugs | Therapy, Investigational | Laboratory Procedures | Imaging studies | Scientific investigation
Item
14. current participation in any other clinical study or research project which involves administration of a pharmaceutical product or experimental treatment, or which involves protocol-specified laboratory tests, imaging studies or other investigations.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C0949266 (UMLS CUI [3])
C0022885 (UMLS CUI [4])
C1881134 (UMLS CUI [5])
C0683933 (UMLS CUI [6])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial